Which agent should be considered in ischemic-type chest discomfort along with aspirin and nitro?

Which agent should be considered in ischemic-type chest discomfort along with aspirin and nitro?

• A. Beta-blockers
• B. ACE inhibitors
• C. P2Y inhibitors
• D. Statins

Answer: (C)

In ischemic chest discomfort such as an acute coronary syndrome, you treat with dual antiplatelet therapy to prevent further clot growth. Adding a P2Y12 inhibitor to aspirin is the key move. P2Y12 inhibitors block the ADP receptor on platelets, stopping ADP-driven platelet activation and aggregation. When combined with aspirin, which blocks thromboxane A2 formation, this two-pronged approach more effectively reduces the risk of recurrent ischemia and supports reperfusion strategies. Other agents like beta-blockers, ACE inhibitors, or statins are important in ACS management, but they address different aspects—heart rate and demand, afterload and remodeling, or cholesterol and plaque stabilization—and aren’t the immediate antiplatelet pairing with aspirin and nitro in the acute setting.

In ischemic chest discomfort such as an acute coronary syndrome, you treat with dual antiplatelet therapy to prevent further clot growth. Adding a P2Y12 inhibitor to aspirin is the key move. P2Y12 inhibitors block the ADP receptor on platelets, stopping ADP-driven platelet activation and aggregation. When combined with aspirin, which blocks thromboxane A2 formation, this two-pronged approach more effectively reduces the risk of recurrent ischemia and supports reperfusion strategies.

Other agents like beta-blockers, ACE inhibitors, or statins are important in ACS management, but they address different aspects—heart rate and demand, afterload and remodeling, or cholesterol and plaque stabilization—and aren’t the immediate antiplatelet pairing with aspirin and nitro in the acute setting.